How Ovarian Cancer Cells Develop Chemo Resistance-and How to Overcome It

Text
Researchers at Michigan State University have identified a protein, TPPP3, that plays a critical role in ovarian cancer cells developing resistance to chemotherapy, according to a study published in Cell Reports. Blocking this protein restored the effectiveness of cisplatin, a standard chemotherapy drug, in laboratory models, offering a potential new strategy to combat treatment resistance.

Text
The study focused on cisplatin, a chemotherapy agent widely used for ovarian cancer and other malignancies. While it is known to damage cancer cells’ DNA, the research revealed another mechanism: the drug also disrupts microtubules, the structural components that help cells survive. Sachi Horibata, an assistant professor at Michigan State University’s Precision Health Program, said the findings explain how cancer cells adapt to chemotherapy by altering their internal structure.

Text
“Cancer cells can reprogram what we call the ‘tubulin code’—a set of structural changes that stabilize microtubules and support survival under stress,” Horibata said. “This adaptation allows them to withstand treatment and ultimately resist chemotherapy.” The protein TPPP3, the study found, acts as a shield for cancer cells by stabilizing microtubules. Higher levels of TPPP3 correlated with greater resistance to cisplatin and carboplatin, while lower levels were associated with improved patient outcomes.

Text
In experiments, removing TPPP3 from cancer cells restored their sensitivity to cisplatin, suggesting that targeting the protein could enhance existing therapies. “This discovery could help explain why some patients achieve remission only for cancer to return stronger later,” Horibata said. The research builds on her personal motivation: her grandmother’s experience with ovarian cancer, which she made her life’s work to understand.

Text
The findings highlight a shift in understanding cancer treatment resistance. Rather than focusing solely on DNA damage, the study emphasizes the role of cellular structure. “By targeting microtubule stability, we may improve the durability of current therapies instead of replacing them,” said Horibata, who is one of the lead researchers on the study.

Text
The research team included collaborators from Michigan State University, the National Institutes of Health (NIH), and other institutions. Funding came from multiple sources, including the NIH’s Intramural Research Program, the Japan Society for the Promotion of Science, and the National Heart and Lung Institute.

Text
The study also has broader implications for understanding chemotherapy side effects. Microtubules are essential in healthy cells, and the research could shed light on why treatments like cisplatin often cause nerve damage, hair loss, and hearing loss.

Text
Researchers are now exploring ways to translate the findings into clinical applications. This includes developing drugs that target TPPP3 and testing its potential as a biomarker to identify patients at risk of resistance. Future studies will examine how the protein interacts with existing chemotherapy combinations and whether the mechanism applies to other cancer types.

Text
“This is about staying one step ahead of cancer,” Horibata said. “If we can block how tumors adapt to treatment, we can make existing therapies more effective and personalized for each patient.”

Text
The study represents a significant contribution to ovarian cancer research. It underscores the importance of understanding cellular mechanisms beyond genetic mutations, offering hope for more resilient treatment strategies.

Quoted text
“We have learned how cancer cells adapt to chemotherapy by altering their internal structure,” says Sachi Horibata, assistant professor in the Precision Health Program and pharmacology and toxicology department at the Michigan State University College of Human Medicine and one of the lead researchers on the study.
Source
Quoted text
“TPPP3 acts like a protective shield for cancer cells,” Horibata says. “When we remove it, we weaken the cell’s defenses and allow chemotherapy to work more effectively.”
Source
Quoted text
“This is about staying one step ahead of cancer,” Horibata says. “If scientists can understand how tumors adapt to survive treatment, we can start to block that process—making existing therapies more effective, more durable and ultimately more personalized for each patient.”
Source